Weiss Ratings Reaffirms Hold (C) Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Key Points

• Weiss Ratings has reaffirmed a "hold (C)" rating for Collegium Pharmaceutical (NASDAQ: COLL), while other analysts have issued mixed ratings including a "strong-buy" and a "buy."
• Collegium Pharmaceutical's stock price decreased by 0.7% to $35.30, with an average rating of "Buy" and a consensus price target of $42.33.
• The company initiated a stock buyback program allowing it to repurchase up to $150 million in shares, indicating management believes the stock is undervalued.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report)'s stock had its "hold (c)" rating reissued by research analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 18th. HC Wainwright upgraded shares of Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price objective on the stock in a research note on Monday, August 11th. Finally, Zacks Research upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $42.33.

Collegium Pharmaceutical Stock Down 0.7%

NASDAQ:COLL traded down $0.24 during midday trading on Friday, hitting $35.30. 181,801 shares of the company were exchanged, compared to its average volume of 330,173. The company has a fifty day simple moving average of $36.08 and a 200 day simple moving average of $32.01. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $39.95. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27. The company has a market capitalization of $1.11 billion, a PE ratio of 33.94 and a beta of 0.65.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The business had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical announced that its board has initiated a stock buyback program on Monday, July 7th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the specialty pharmaceutical company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board believes its shares are undervalued.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Gino Santini sold 5,405 shares of Collegium Pharmaceutical stock in a transaction on Friday, August 15th. The shares were sold at an average price of $37.19, for a total value of $201,011.95. Following the transaction, the director owned 95,042 shares in the company, valued at $3,534,611.98. This trade represents a 5.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Gordon Freund sold 11,659 shares of Collegium Pharmaceutical stock in a transaction on Friday, August 8th. The shares were sold at an average price of $34.36, for a total value of $400,603.24. Following the completion of the transaction, the director owned 23,129 shares in the company, valued at $794,712.44. The trade was a 33.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,792 shares of company stock valued at $2,084,207 over the last three months. Insiders own 2.51% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its stake in shares of Collegium Pharmaceutical by 1.4% in the 2nd quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company's stock valued at $863,000 after purchasing an additional 409 shares in the last quarter. SummerHaven Investment Management LLC lifted its stake in shares of Collegium Pharmaceutical by 2.1% in the 2nd quarter. SummerHaven Investment Management LLC now owns 24,868 shares of the specialty pharmaceutical company's stock valued at $735,000 after purchasing an additional 514 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Collegium Pharmaceutical by 0.6% in the 2nd quarter. Legal & General Group Plc now owns 89,829 shares of the specialty pharmaceutical company's stock valued at $2,656,000 after purchasing an additional 531 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Collegium Pharmaceutical by 6.9% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,252 shares of the specialty pharmaceutical company's stock valued at $244,000 after buying an additional 534 shares in the last quarter. Finally, Sei Investments Co. lifted its position in Collegium Pharmaceutical by 5.5% during the second quarter. Sei Investments Co. now owns 11,436 shares of the specialty pharmaceutical company's stock valued at $338,000 after buying an additional 600 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.